Metabolic profiling of rat brain and cognitive behavioral tasks: Potential complementary strategies in preclinical cognition enhancement research

Journal of Proteome Research

Volumn 8, Issue 12, 2009, Pages 5679-5690

  Goh, Dilys P Q ^a   Neo, Aveline H ^b   Goh, Catherine W ^b   Aw, Chiu Cheong ^b   New, Lee Sun ^a   Chen, Woei Shin ^b   Atcha, Zeenat ^b   Browne, Edward R ^b   Chan, Eric C Y ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GLAXOSMITHKLINE   (Singapore)

Author keywords

Alzheimer's disease; Chemometric; Cognitive behavioral tests; Donepezil; Galantamine; Metabolic profiling; Metabonomics; UPLC MS MS

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; ADRENALIN; ALANINE; ALPHA METHYLDOPAMINE; ASPARTIC ACID; BIOLOGICAL MARKER; CHOLINE; DONEPEZIL; DOPAMINE; GALANTAMINE; GLUTAMIC ACID; GLYCINE; HISTAMINE; INOSITOL; NORADRENALIN; PARACETAMOL; PHENYLALANINE; SALICYLIC ACID; SEROTONIN; SUCCINIC ACID; TRYPTOPHAN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BEHAVIOR CHANGE; BRAIN; COGNITION; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG RESPONSE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAZE TEST; METABOLIC PARAMETERS; METABOLITE; METABOLOMICS; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEIVER OPERATING CHARACTERISTIC;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; COGNITION; GALANTAMINE; INDANS; MALE; METABOLOME; PIPERIDINES; RATS; RATS, INBRED STRAINS; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 71549153782     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900795g     Document Type: Article

References (61)

1. Weiner, H. L.; Frenkel, D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 2006, 6 (5), 404-416.
2. Blasko, I.; Grubeck-Loebenstein, B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003, 20 (2), 101-113. (Pubitemid 36246292)
3. Tsai, K. J.; Tsai, Y. C.; Shen, C. K. J. G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J. Exp. Med. 2007, 204 (6), 1273-1280. (Pubitemid 46919864)
4. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimer's Dis. 2004, 6 (4), 367-377. (Pubitemid 39287248)
5. Sarter, M. Preclinical research into cognition enhancers. Trends Pharmacol. Sci. 2006, 27 (11), 602-608.
6. Sarter, M. Animal cognition: Defining the issues. Neurosci. Biobehav. Rev. 2004, 28 (7), 645-650.
7. Sarter, M. Taking stock of cognition enhancers. Trends Pharmacol. Sci. 1991, 12 (12), 456-461.
8. Decker, M. W. Animal models of cognitive function. Crit. Rev. Neurobiol. 1995, 9 (4), 321-343.
9. Sarasa, M. Experimental models for Alzheimer's disease research. Rev. Neurol. 2006, 42 (5), 297-301. (Pubitemid 47378396)
10. Pepeu, G. Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2001, 25 (1), 193-209. (Pubitemid 32173792)
11. Myhrer, T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res. Rev. 2003, 41 (2-3), 268-287. (Pubitemid 36355883)
12. Woodruff-Pak, D. S. Preclinical experiments on cognition enhancement in Alzheimer's disease: Drugs affecting nicotinic acetylcholine receptors. Drug Dev. Res. 2002, 56 (3), 335-346.
13. Trinchese, F.; Liu, S.; Ninan, I.; Puzzo, D.; Jacob, J. P.; Arancio, O. Cell cultures from animal models of Alzheimer's disease as a tool for faster screening and testing of drug efficacy. J. Mol. Neurosci. 2004, 24 (1), 15-21. (Pubitemid 41359163)
14. Sowell, R. A.; Owen, J. B.; Allan Butterfield, D. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res. Rev. 2009, 8 (1), 1-17.
15. Tareke, E.; Bowyer, J. F.; Doerge, D. R. Quantification of rat brain neurotransmitters and metabolites using liquid chromatography/electrospray tandem mass spectrometry and comparison with liquid chromatography/ electrochemical detection. Rapid Commun. Mass Spectrom. 2007, 21 (23), 3898-3904.
16. Falangola, M. F.; Dyakin, V. V.; Lee, S. P.; Bogart, A.; Babb, J. S.; Duff, K.; Nixon, R.; Helpern, J. A. Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease. NMR Biomed. 2007, 20 (3), 343-351.
17. Sykova, E.; Vorisek, I.; Antonova, T.; Mazel, T.; Meyer-Luehmann, M.; Jucker, M.; Hajek, M.; Or, M.; Bures, J. Changes in extracellular space size and geometry in APP23 transgenic mice: A model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (2), 479-484. (Pubitemid 40116792)
18. Lanari, A.; Amenta, F.; Silvestrelli, G.; Tomassoni, D.; Parnetti, L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev. 2006, 127 (2), 158-165. (Pubitemid 43165614)
19. Garcia-Alloza, M.; Gil-Bea, F. J.; Diez-Ariza, M.; Chen, C. P. L. H.; Francis, P. T.; Lasheras, B.; Ramirez, M. J. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005, 43 (3), 442-449. (Pubitemid 40222131)
20. Schweizer, T.; Birthelmer, A.; Lazaris, A.; Cassel, J. C.; Jackisch, R. 3,4-DAP-evoked transmitter release in hippocampal slices of aged rats with impaired memory. Brain Res. Bull. 2003, 62 (2), 129-136. (Pubitemid 37443658)
21. Kalkman, H. O.; Subramanian, N.; Hoyer, D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001, 25 (6), 904-914. (Pubitemid 34031895)
22. Atcha, Z.; Chen, W. S.; Ong, A. B.; Wong, F. K.; Neo, A.; Browne, E. R.; Witherington, J.; Pemberton, D. J. Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology 2009; DOI: 10.1007/s00213-009-1620-6.
23. Fone, K. C. F. An update on the role of the 5-hydroxytryptamine receptor in cognitive function. Neuropharmacology 2008, 55 (6), 1015-1022.
24. Siegel, G. J. Basic neurochemistry: molecular, cellular, and medical aspects, 7th ed.; Elsevier: Amsterdam; Boston, 2006.
25. Rutten, K.; Prickaerts, J.; Blokland, A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol. Learn. Mem. 2006, 85 (2), 132-138. (Pubitemid 43247839)
26. Abe, H.; Ishida, Y.; Iwasaki, T. Perirhinal N-methyl-D-aspartate and muscarinic systems participate in object recognition in rats. Neurosci. Lett. 2004, 356 (3), 191-194.
27. Obinu, M. C.; Reibaud, M.; Miquet, J. M.; Pasquet, M.; Rooney, T. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2002, 26 (5), 913-918. (Pubitemid 35245559)
28. Chopin, P.; Colpaert, F. C.; Marien, M. Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J. Pharmacol. Exp. Ther. 2002, 301 (1), 187-196. (Pubitemid 34250294)
29. Dodart, J. C.; Mathis, C.; Ungerer, A. Scopolamine-induced deficits in a two-trial object recognition task in mice. NeuroReport 1997, 8 (5), 1173-1178. (Pubitemid 27198592)
30. Bartolini, L.; Casamenti, F.; Pepeu, G. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol., Biochem. Behav. 1996, 53 (2), 277-283. (Pubitemid 26059192)
31. Ennaceur, A.; Meliani, K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory. Behav. Brain Res. 1992, 51 (1), 83-92.
32. Kamei, H.; Nagai, T.; Nakano, H.; Togan, Y.; Takayanagi, M.; Takahashi, K.; Kobayashi, K.; Yoshida, S.; Maeda, K.; Takuma, K.; Nabeshima, T.; Yamada, K. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol. Psychiatry 2006, 59 (1), 75-84. (Pubitemid 43005238)
33. Hotte, M.; Thuault, S.; Lachaise, F.; Dineley, K. T.; Hemmings, H. C.; Nairn, A. C.; Jay, T. M. D1 receptor modulation of memory retrieval performance is associated with changes in pCREB and pDARPP-32 in rat prefrontal cortex. Behav. Brain Res. 2006, 171 (1), 127-133.
34. Chuhan, Y. S.; Taukulis, H. K. Impairment of single-trial memory formation by oral methylphenidate in the rat. Neurobiol. Learn. Mem. 2006, 85 (2), 125-131.
35. Hotte, M.; Naudon, L.; Jay, T. M. Modulation of recognition and temporal order memory retrieval by dopamine D1 receptor in rats. Neurobiol. Learn. Mem. 2005, 84 (2), 85-92.
36. Ventura, R.; Pascucci, T.; Catania, M. V.; Musumeci, S. A.; Puglisi-Allegra, S. Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: Involvement of dopamine in the medial prefrontal cortex. Behav. Pharmacol. 2004, 15 (5-6), 433-442. (Pubitemid 39238357)
37. Woolley, M. L.; Marsden, C. A.; Sleight, A. J.; Fone, K. C. F. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology 2003, 170 (4), 358-367.
38. Winters, B. D.; Bussey, T. J. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J. Neurosci. 2005, 25 (17), 4243-4251. (Pubitemid 40628768)
39. de Lima, M. N. M.; Laranja, D. C.; Bromberg, E.; Roesler, R.; Schroder, N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav. Brain Res. 2005, 156 (1), 139-143. (Pubitemid 39330444)
40. Sargolini, F.; Roullet, P.; Oliverio, A.; Mele, A. Effects of intra-accumbens focal administrations of glutamate antagonists on object recognition memory in mice. Behav. Brain Res. 2003, 138 (2), 153-163. (Pubitemid 36071354)
41. Baker, K. B.; Kim, J. J. Effects of stress and hippocampal NMDA receptor antagonism on recognition memory in rats. Learn. and Mem. 2002, 9 (2), 58-65. (Pubitemid 34507492)
42. Roullet, P.; Sargolini, F.; Oliverio, A.; Mele, A. NMDA and AMPA antagonist infusions into the ventral striatum impair different steps of spatial information processing in a nonassociative task in mice. J. Neurosci. 2001, 21 (6), 2143-2149.
43. Schiapparelli, L.; Simon, A. M.; Del Rio, J.; Frechilla, D. Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: Correlation with AMPA receptor subunit expression in rat hippocampus. Neuropharmacology 2006, 50 (7), 897-907. (Pubitemid 43737006)
44. Pitsikas, N.; Tsitsirigou, S.; Zisopoulou, S.; Sakellaridis, N. The 5-HT1A receptor and recognition memory: Possible modulation of its behavioral effects by the nitrergic system. Behav. Brain Res. 2005, 159 (2), 287-293. (Pubitemid 40462504)
45. Pitsikas, N.; Sakellaridis, N. The 5-HT2C receptor antagonist RO 60-0491 counteracts rats' retention deficits in a recognition memory task. Brain Res. 2005, 1054 (2), 200-202. (Pubitemid 41219350)
46. Pitsikas, N.; Rigamonti, A. E.; Cella, S. G.; Muller, E. E. The 5-HT1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Res. 2003, 983 (1-2), 215-222.
47. Bonvento, G.; Scatton, B.; Claustre, Y.; Rouquier, L. Effect of local injection of 8-OH-DPAT into the dorsal or median raphe nuclei on extracellular levels of serotonin in serotonergic projection areas in the brain. Neurosci. Lett. 1992, 137 (1), 101-104.
48. Invernizzi, R.; Carli, M.; Di Clemente, A.; Samanin, R. Administration of 8-hydroxy-2-(di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: Differences in potency and regional sensitivity. J. Neurochem. 1991, 56 (1), 243-247. (Pubitemid 21901955)
49. Hernandez, C. M.; Gearhart, D. A.; Parikh, V.; Hohnadel, E. J.; Davis, L. W.; Middlemore, M. L.; Warsi, S. P.; Waller, J. L.; Terry Jr, A. V. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J. Pharmacol. Exp. Ther. 2006, 316 (2), 679-694.
50. Dimitrova, D. S.; Getova-Spassova, D. P. Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia. J. Pharmacol. Sci. 2006, 101 (3), 199-204.
51. Barnes, C. A.; Meltzer, J.; Houston, F.; Orr, G.; McGann, K.; Wenk, G. L. Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000, 99 (1), 17-23.
52. Montgomery, A. M. J.; Grottick, A. J. Neurotransmitter system interactions revealed by drug-induced changes in motivated behavior. Pharmacol., Biochem. Behav. 1999, 62 (4), 643-657.
53. Nieoullon, A.; Kerkerian-Le Goff, L. Cellular interactions in the striatum involving neuronal systems using 'classical' neurotransmitters: Possible functional implications. Movement Disord. 1992, 7 (4), 311-325.
54. Geerts, H.; Guillaumat, P. O.; Grantham, C.; Bode, W.; Anciaux, K.; Sachak, S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res. 2005, 1033 (2), 186-193. (Pubitemid 40193413)
55. Jones, R. W.; Soininen, H.; Hager, K.; Aarsland, D.; Passmore, P.; Murthy, A.; Zhang, R.; Bahra, R. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int. J. Geriatr. Psychiatry 2004, 19 (1), 58-67. (Pubitemid 38180693)
56. Aguglia, E.; Onor, M. L.; Saina, M.; Maso, E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr. Med. Res. Opin. 2004, 20 (11), 1747-1752. (Pubitemid 39611933)
57. Harry, R. D.; Zakzanis, K. K. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: A meta-analysis. Human Psychopharmacol. 2005, 20 (3), 183-187.
58. Hansen, R. A.; Gartlehner, G.; Lohr, K. N.; Kaufer, D. I. Functional outcomes of drug treatment in Alzheimer's disease - A systematic review and meta-analysis. Drugs Aging 2007, 24 (2), 155-167. (Pubitemid 46327574)
59. Hansen, R. A.; Gartlehner, G.; Webb, A. P.; Morgan, L. C.; Moore, C. G.; Jonas, D. E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin. Interventions Aging 2008, 3, 211-225.
60. Takeda, A.; Loveman, E.; Clegg, A.; Kirby, J.; Picot, J.; Payne, E.; Green, C. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2006, 21 (1), 17-28. (Pubitemid 43141491)
61. Cumbo, E. Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Primary Care Community Psychiatry 2005, 10 (3), 95-102. (Pubitemid 43355657)